Pharvaris N.V. (PHVS)
NasdaqGS · Biotechnology
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
Pharvaris N.V. is trading at $30.68, up 0.07% on the session. The 50 day average sits at $34.03 and the 200 day at $30.79, which puts the stock in a uptrend. RSI is at 43.8, which reads as weak, and MACD is bullish crossover. Volume is below average.
The nearest support is around $30.15 with resistance near $32.32, so that band frames the current range. Average daily movement is roughly $1.50, or about 4.9% of the share price, which is what any stop placement has to allow for. The overall health score of 45 out of 100 combines a trend score of 33, momentum of 50 and a risk score of 56.
Technical indicators
AI trade signals on PHVS
All signals| Date | Setup | Entry | Target | Stop | R:R | Status |
|---|---|---|---|---|---|---|
| Sep 14 | Breakout | ••.•• | ••.•• | ••.•• | 1.69:1 | Stopped Out |
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Company website